Resumen de acción ABUS
Arbutus Biopharma Corporation, empresa biofarmacéutica, desarrolla en Estados Unidos nuevas terapias contra la infección crónica por el virus de la hepatitis B (VHB).
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
Competidores de Arbutus Biopharma Corporation
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.73 |
| 52 Week High | US$3.29 |
| 52 Week Low | US$1.69 |
| Beta | 2.09 |
| 1 Month Change | 5.00% |
| 3 Month Change | 14.71% |
| 1 Year Change | 8.76% |
| 3 Year Change | -21.33% |
| 5 Year Change | 4.60% |
| Change since IPO | -61.22% |
Noticias y actualizaciones recientes
Moderna Investors Should Beware Patent-Dispute Fallout
Apr 23Arbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty Remains
Apr 10Recent updates
Moderna Investors Should Beware Patent-Dispute Fallout
Apr 23Arbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty Remains
Apr 10Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation
Feb 10
Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Jan 03Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week
Nov 09Some Shareholders Feeling Restless Over Arbutus Biopharma Corporation's (NASDAQ:ABUS) P/S Ratio
Oct 24We're Interested To See How Arbutus Biopharma (NASDAQ:ABUS) Uses Its Cash Hoard To Grow
Apr 26Broker Revenue Forecasts For Arbutus Biopharma Corporation (NASDAQ:ABUS) Are Surging Higher
Nov 11We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth
Oct 28Arbutus Biopharma: Our Current Take On This 2 Buck 'Soap Opera'
Sep 12Arbutus stock rises on US patent linked to hepatitis B therapy AB-729
Aug 30Brokers Are Upgrading Their Views On Arbutus Biopharma Corporation (NASDAQ:ABUS) With These New Forecasts
Aug 06Arbutus Biopharma, Assembly Biosciences plan to continue their hepatitis B mid-stage trial
Jul 20Arbutus: 2 Key Catalysts To Look Forward To After EASL Data Release
Jun 29We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth
Jun 15Rainbows and Unicorns: Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Just Became A Lot More Optimistic
May 11Need To Know: Analysts Are Much More Bullish On Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenues
Mar 08Arbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of Interest
Mar 07Arbutus Biopharma: How Will Patent Win Impact Stock Outlook?
Dec 17Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans
Dec 14Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment
Nov 20Arbutus Biopharma: A First Assessment
Sep 15We're Keeping An Eye On Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate
Sep 11Arbutus' Recent Hepatitis B Data At EASL 2021 Makes The Case For A Great Long-Term Investment
Jun 29Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans
May 21Arbutus Bio slips 4% as Q1 revenue trails consensus
May 05What You Need To Know About Arbutus Biopharma Corporation's (NASDAQ:ABUS) Investor Composition
Mar 12We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth
Feb 02Arbutus Biopharma's (NASDAQ:ABUS) Stock Price Has Reduced 29% In The Past Three Years
Jan 07Arbutus Biopharma (ABUS) Investor Presentation - Slideshow
Dec 17Rentabilidad de los accionistas
| ABUS | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 0.4% | -0.2% | 2.9% |
| 1Y | 8.8% | -1.0% | 22.2% |
Rentabilidad vs. Industria: ABUS superó al sector US Biotechs , que obtuvo un rendimiento del 0.7% el año pasado.
Rentabilidad vs. Mercado: ABUS obtuvo unos resultados inferiores a los del mercado US, que fue del 24.9% el año pasado.
Volatilidad de los precios
| ABUS volatility | |
|---|---|
| ABUS Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: ABUS no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de ABUS (7%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| n/a | 73 | Mike McElhaugh | www.arbutusbio.com |
Arbutus Biopharma Corporation, empresa biofarmacéutica, desarrolla en Estados Unidos nuevos tratamientos para la infección crónica por el virus de la hepatitis B (VHB). Su cartera de productos contra el VHB consiste en imdusiran (AB-729), un candidato a producto terapéutico de ARNi de administración subcutánea que suprime todos los antígenos del VHB, incluida la expresión del HBsAg. Los programas de investigación y desarrollo de la empresa incluyen AB-101, un inhibidor oral de PD-L1 para reactivar el sistema inmunitario específico del VHB de los pacientes; y medicamentos antivirales de moléculas pequeñas para tratar coronavirus, incluido COVID-19.
Resumen de fundamentos de Arbutus Biopharma Corporation
| Estadísticas fundamentales de ABUS | |
|---|---|
| Capitalización bursátil | US$491.88m |
| Beneficios(TTM) | -US$72.85m |
| Ingresos (TTM) | US$18.14m |
27.1x
Ratio precio-ventas (PS)-6.8x
Ratio precio-beneficio (PE)¿Está ABUS sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ABUS | |
|---|---|
| Ingresos | US$18.14m |
| Coste de los ingresos | US$73.70m |
| Beneficio bruto | -US$55.56m |
| Otros gastos | US$17.29m |
| Beneficios | -US$72.85m |
Últimos beneficios comunicados
Dec 31, 2023
Próxima fecha de beneficios
May 02, 2024
| Beneficios por acción (BPA) | -0.40 |
| Margen bruto | -306.26% |
| Margen de beneficio neto | -401.57% |
| Ratio deuda/patrimonio | 6.6% |
¿Cómo se ha desempeñado ABUS a largo plazo?
Ver rendimiento histórico y comparativa